NEOG — Q1 2026 Financial Report Analysis (Fiscal Q1 2027)

Sales growth is back, and the operating loss has nearly closed

Neogen sells the test kits food plants use to check for bacteria such as Listeria and Salmonella, plus animal-health products (veterinary instruments, insect and rodent control) and genetic testing for livestock. In its fiscal first quarter (the three months to August 31, 2026; Neogen's fiscal year ends May 31, so this is Q1 of fiscal 2027), revenue rose 6.5% to $222.8 million. The operating loss shrank from $16.1 million to $1.8 million.

The headline net result went the other way. Neogen posted a $11.9 million net loss ($0.05 per share), compared with a $36.3 million profit a year earlier. That reversal says nothing about this year's business. Last year's quarter included a $76.4 million one-time gain from selling the Cleaners & Disinfectants business. Without that gain, last year's quarter would also have been a loss.

At a glance

• Revenue +6.5% to $222.8M; +8.1% on a "core" basis. Core growth strips out currency moves and businesses sold or discontinued. About 3 points of that core growth came from timing: some distributors cut their stock a year ago, and some customer orders landed early this quarter. The underlying pace is closer to 5%.
• Gross margin 47.4%, up from 45.4%. Gross margin is the share of sales left after the direct cost of making the product. Most of the 2-point gain came from cheaper manufacturing of sample-collection products after a costly move out of 3M's plants.
• Food Safety segment profit more than doubled, from $7.2M to $16.3M. Its margin rose from about 4.7% to 10.0% of segment sales.

The numbers

Segment growth rates are from the 10-Q's own table, which uses rounded millions. The earnings release shows 7.4% and 4.2% using unrounded figures.

Where the growth came from

Food Safety ($163.2M, 73% of revenue). The 10-Q credits $12.3 million of business growth, "led by higher sales of pathogen detection products, indicator and sample collection products," plus $1.2 million from currency. A $2.4 million drop, mainly from the divested cleaners business, offset part of that. By product line, Indicator Testing & Culture Media grew from $76.8M to $85.6M (+11.5%). This is the line that includes Petrifilm, the ready-made culture plates Neogen bought from 3M in 2022. Bacterial & General Sanitation, which includes the pathogen tests, grew from $41.6M to $44.6M (+7.2%). Two Food Safety lines shrank: Natural Toxins & Allergens ($20.0M to $19.3M) and Biosecurity ($5.8M to $4.6M).

Animal Safety ($59.6M). Reported growth was only 4.4% because the cleaners sale removed $2.5 million. Excluding that, core growth was 8.0%. Veterinary Instruments & Consumables led, rising from $11.9M to $14.1M (+18.5%), with insect-control products also stronger. Management points to a better livestock backdrop: US cattle herds are near multi-decade lows, cattle prices are high and the USDA expects herds to grow again. It also says the supplier quality problems that hurt this segment in fiscal 2026 have "largely improved." Segment operating income rose from $4.5M to $7.5M, a margin of 12.6%, up from 7.9%.

By region, US revenue rose from $102.1M to $110.1M (+7.8%) and international from $107.1M to $112.7M (+5.2%). The release says every region grew, with double-digit growth in Asia Pacific.

Why the operating loss shrank

The $14.3 million improvement in operating result has three sources:

• $10.5M more gross profit. The 10-Q credits higher volumes, price increases and favorable currency. Higher costs from running Petrifilm production in two places partly offset these gains. Sample-collection "transition and ramp-up costs" fell from $6.0M a year ago to zero.
• $3.6M less sales and marketing spend, from lower outbound shipping and fewer staff after the roughly 10% headcount cut Neogen started in fiscal 2026.
• $1.6M less general and administrative (G&A) spend, mainly from lower stock-based pay. Research and development rose $1.4M to $6.5M as Neogen hired for new products.

Neogen still reports an operating loss despite healthy segment profits because of $23.0 million of amortization in G&A. Amortization is a non-cash charge that spreads the cost of intangible assets bought in the 3M deal over time. That charge alone is larger than the $23.8M of combined segment operating income. Below the operating line, interest expense fell from $15.5M to $13.8M as debt came down.

What the headline numbers hide

• The net loss is accounting, not cash burn. Operating cash flow was $12.9M, positive, against the $11.9M net loss. The gap comes mainly from $29.1M of depreciation and amortization, which reduce profit but cost no cash. However, free cash flow (cash from operations minus spending on equipment) was only $4.7M. That figure was helped by capital spending falling from $24.0M to $8.2M. Management expects about $40M of capital spending for the full year, about $10M a quarter, which is more than Q1's $8.2M.
• The gap between GAAP and adjusted results is large, and part of it repeats every quarter. Adjusted net income was $17.5M versus a GAAP loss of $11.9M, a $29.4M difference. The biggest add-back is $22.3M of acquisition amortization, which is a fair exclusion. But the list also includes $5.6M of Petrifilm duplicate manufacturing costs, $5.1M of "transformation initiatives" (consulting, ERP software rollout, severance), $3.1M of stock-based pay and $1.5M of deal costs. Transformation costs were also excluded a year ago ($6.6M), so they behave more like an ongoing cost than a one-off. The GAAP result also includes a $2.8M one-time gain from revaluing a contingent payment owed on an earlier acquisition (CAPInnoVet). This gain helps "other income" this quarter, and the adjusted figures remove it.
• About 3 points of growth won't repeat. The release says core growth "includes a benefit of approximately 3%" from distributor stock cuts a year ago and from order timing this quarter. Growth on a cleaner basis was roughly 5%.
• Working capital looks clean. Receivables (money customers owe) fell from $146.8M to $136.2M during the quarter. Gross inventory was nearly flat ($161.5M to $162.7M), although work-in-process rose from $8.0M to $11.9M. Neither is building up faster than sales.
• Per-share results got no help from buybacks or tax. Neogen bought back no shares, and its diluted share count rose slightly (217.3M to 218.1M). The release says adjusted EPS rose because of higher EBITDA, lower interest expense ($1.7M less) and lower income tax expense.

Takeaway: The core business is now profitable before acquisition amortization, with segment operating income up from $11.7M to $23.8M. The next test is the Petrifilm manufacturing handover starting in November 2026. Over the past year, Petrifilm duplicate costs have more than doubled, from $2.3M to $5.6M a quarter. Whether they fall away on schedule, without supply problems like those in the sample-collection move, will decide whether margins keep improving.

Debt and the pending Genomics sale

Total debt fell from $800.0M to $780.0M after a $20M term-loan prepayment in June. Neogen repaid another $10M in September. With $172.0M of cash, net debt is about $608M. By our calculation, that is roughly 3.3 times the midpoint of management's full-year adjusted EBITDA guidance. Neogen says it complies with its loan covenants and has no required term-loan principal payments until fiscal 2029.

Neogen agreed in March 2026 to sell its Genomics business to Zoetis for $160.0 million. Australian and New Zealand competition regulators moved their reviews into a second phase in July, and both reviews are expected to conclude by the end of December 2026. Genomics brought in $24.0M of revenue this quarter ($6.7M in Food Safety, $17.3M in Animal Safety), about 11% of the total. When the sale closes, reported revenue will step down by about that much, and the proceeds could cut net debt by about a quarter. The release does not say whether the new guidance assumes the sale closes during the fiscal year.

Outlook

Management raised its fiscal 2027 guidance (year ending May 31, 2027):

The raise is small: $5M on revenue and $1M on adjusted EBITDA. At the midpoints, the remaining three quarters need about $222M of revenue each, roughly flat with Q1. Adjusted EBITDA would need to average about $47M a quarter, a margin near 21% versus 18.7% in Q1. So the guidance assumes margins improve as the year goes on while sales growth slows, partly because the ~3-point timing benefit drops out. The Petrifilm handover starting in November is the main way margins can improve. It is also the main execution risk: Neogen had expensive delays when it moved sample-collection production out of 3M's plants in fiscal 2025.

What to watch next quarter (Q2 FY2027, to November 30, 2026): whether Petrifilm duplicate costs peak and start to fall; whether core growth holds near 5% without the timing benefit; and whether the Genomics sale closes by December, which would bring in $160M to pay down debt.